Literature DB >> 27973689

Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry.

L Naldi1,2, S Cazzaniga1,3, M Di Mercurio1, E Grossi4,5, A Addis6.   

Abstract

BACKGROUND: Limited evidence is available on the impact of socioeconomic factors on drug prescriptions for psoriasis.
OBJECTIVES: To investigate factors influencing prescription of conventional vs. biological treatment for patients with psoriasis, based on the Italian Psocare registry, with a special focus on socioeconomic factors.
METHODS: This was a cross-sectional study evaluating the baseline data of patients included in the Psocare registry. All of the consecutive adult patients with a diagnosis of chronic plaque psoriasis or psoriatic arthritis who were prescribed a systemic treatment for psoriasis at participating centres were included in this study. Univariate and multivariate analyses of the baseline factors associated with a biologics prescription were performed.
RESULTS: From September 2005 to September 2009, 12 838 patients were identified. A multivariate analysis revealed that, among other factors, completing a level of education higher than lower secondary school and being employed as a manager or a professional were independent factors associated with a biologics prescription at entry in the registry. Additional analyses on the association between these two variables and a severe psoriasis condition [Psoriasis Area Severity Index (PASI) score > 20] revealed a significantly increasing trend of severe disease towards lower educational attainment, while unemployed patients were more likely to have a more severe condition compared with the other categories of workers.
CONCLUSIONS: We documented inequalities of drug prescriptions for psoriasis in Italy, with a trend towards a higher frequency of prescription for more expensive biologics in higher socioeconomic sectors of the population.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27973689     DOI: 10.1111/bjd.15234

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

Review 1.  The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?

Authors:  Gianluca Trifirò; Rosa Gini; Francesco Barone-Adesi; Ettore Beghi; Anna Cantarutti; Annalisa Capuano; Carla Carnovale; Antonio Clavenna; Mirosa Dellagiovanna; Carmen Ferrajolo; Matteo Franchi; Ylenia Ingrasciotta; Ursula Kirchmayer; Francesco Lapi; Roberto Leone; Olivia Leoni; Ersilia Lucenteforte; Ugo Moretti; Alessandro Mugelli; Luigi Naldi; Elisabetta Poluzzi; Concita Rafaniello; Federico Rea; Janet Sultana; Mauro Tettamanti; Giuseppe Traversa; Alfredo Vannacci; Lorenzo Mantovani; Giovanni Corrao
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

2.  Differential characteristics and treatment of psoriasis patients by economic status in South Korea: An analysis of the National Health Insurance Database.

Authors:  Dongmun Ha; Jinchol Ryu; Yoonsoo Chun; Inmyung Song; Ju-Young Shin
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.889

3.  Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project.

Authors:  Gianluca Trifirò; Valentina Isgrò; Ylenia Ingrasciotta; Valentina Ientile; Luca L'Abbate; Saveria S Foti; Valeria Belleudi; Francesca Poggi; Andrea Fontana; Ugo Moretti; Riccardo Lora; Alberto Sabaini; Ilenia Senesi; Carla Sorrentino; Maria R Puzo; Angela Padula; Mariano Fusco; Roberta Giordana; Valentina Solfrini; Aurora Puccini; Paola Rossi; Stefania Del Zotto; Olivia Leoni; Martina Zanforlini; Domenica Ancona; Vito Bavaro; Donatella Garau; Stefano Ledda; Salvatore Scondotto; Alessandra Allotta; Marco Tuccori; Rosa Gini; Giampaolo Bucaneve; David Franchini; Anna Cavazzana; Valeria Biasi; Stefania Spila Alegiani; Marco Massari
Journal:  BioDrugs       Date:  2021-10-12       Impact factor: 5.807

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.